Preface to First Edition - lib

198 SURVIVAL ANALYSISTable 11.1:glioma data (continued).age sex histology group event time40 Female GBM RIT TRUE 1436 Male GBM RIT TRUE 3627 Male Grade3 Control TRUE 3432 Male Grade3 Control TRUE 3253 Female Grade3 Control TRUE 946 Male Grade3 Control TRUE 1933 Female Grade3 Control FALSE 5019 Female Grade3 Control FALSE 4832 Female GBM Control TRUE 870 Male GBM Control TRUE 872 Male GBM Control TRUE 1146 Male GBM Control TRUE 1244 Male GBM Control TRUE 1583 Female GBM Control TRUE 557 Female GBM Control TRUE 871 Female GBM Control TRUE 861 Male GBM Control TRUE 665 Male GBM Control TRUE 1450 Male GBM Control TRUE 1342 Female GBM Control TRUE 25Source: From Grana, C., et. al., Br. J. Cancer, 86, 207–212, 2002. With permission.The effects of hormonal treatment with Tamoxifen in women suffering fromnode-positive breast cancer were investigated in a randomised clinical trial asreported by Schumacher et al. (1994). Data from randomised patients from thistrial and additional non-randomised patients (from the German Breast CancerStudy Group 2, GBSG2) are analysed by Sauerbrei and Royston (1999).Complete data of seven prognostic factors of 686 women are used in Sauerbreiand Royston (1999) for prognostic modelling. Observed hypothetical prognosticfactors are age, menopausal status, tumour size, tumour grade, number ofpositive lymph nodes, progesterone receptor, estrogen receptor and the informationof whether or not a hormonal therapy was applied. We are interestedin an assessment of the impact of the covariates on the survival time of thepatients. A subset of the patient data are shown in Table 11.2.11.2 Survival AnalysisIn many medical studies, the main outcome variable is the time to the occurrenceof a particular event. In a randomised controlled trial of cancer, forexample, surgery, radiation and chemotherapy might be compared with re-© 2010 by Taylor and Francis Group, LLC